|Expense Ratio (net)||1.02%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||Above Average|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Sep 15, 1997|
A burgeoning economy and steady influx of funds make conditions ripe for diversification and further strengthening of the capital base.
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.